

Liposome/drug compatibility and the possibilities for its improvement

Balouch Martin,
Odehnalová K., Storchmannová K., Šrejber M.,
Šoltys M., Petrová E., Konefal M., Janská P.,
Zadrazil A., Brus J., Berka K., Štěpánek F.



Pharmaceutical
Applied Research
Center

ZeNTIVA




Faculty
of Science



UNIVERSITY OF
CHEMISTRY AND TECHNOLOGY
PRAGUE



Liposomes

- composed of phospholipids
- contains hydrophilic pocket
- can carry a cargo



Liposomes state of art

- Significant pharmacological improvement of **few** drugs
- These drugs are mostly high Mw molecules
- Doxorubicin (Doxil®) and analogues prevalent



Question n. 1

Why there are only so few small molecules formulated in liposomes?

Question(s) n. 1

Why there are only so few small molecules formulated in liposomes?

Which molecules can be entrapped in liposomes?

Which molecules can be entrapped in liposomes?


- The key to this answer is permeability

Which molecules can be entrapped in liposomes?

- The key to this answer is permeability
 - Permeability calculation using COSMOPerm
 - Experiments using fluorescent dyes
 - Comparison of both
 - Further COSMOPerm calculation of 56 drugs


COSMOPerm

- Computational approach to permeability
- Based on molecular dynamics and quantum mechanics




Membrane for permeation

- DPPC:DPPG:Chol (75:10:15) – 64 lipids for a leaflet
 - 250+ ns simulation time
 - Simulated using molecular dynamics




Quantum Mechanics optimisation

- All membrane components
- All permeating molecules
 - DFT/BP/TZVP with fine option level of calculation
 - Calculated by Turbomole 6.3 to obtain σ -profile of a molecule



Permeation calculation principle (1/2)

1. Chemical potential of API (μ_i) in each layer (r) and each orientation (d)



2. Partition function from chemical potential


$$Z_i(r) = \sum_d e^{\frac{-\mu_i(r,d)}{kT}}$$

3. Free energy from the partition function

$$\Delta G_i(r) = -RT \ln \frac{Z_i(r)}{Z_i(n)}$$

Permeation calculation principle (2/2)

4. Free energy profile



5. Partitioning


$$K_{\text{lipid/water}} = e^{\frac{-\Delta G_i(\text{min})}{RT}}$$

6. Permeation

$$\frac{1}{P} = \int_{-\frac{L}{2}}^{\frac{L}{2}} \frac{1}{D_i(r)} e^{\frac{G_i(r)}{kT}} dr$$


Calculation of 56 APIs

- From DrugBank Database
- Partitioning and permeation
- Plot into 2D space
- Experimental confirmation (cycloserine)




Space to work with – LBCS

- boxes for sorting molecules
- The proposition of **LBCS – liposome biopharmaceutics classification system**
- Can work as a BCS analogue for liposomes




Comparison of computation and experiment




Dye	„BCS“	Encapsulated?	Thermal release
Carboxyfluorescein (CF)	1-3	YES	YES
Fluorescein (F)	1	Nearly NO	NO
Fluorescein-isothiocyanate (FITC)	2	Something	NO
Calcein	3	NO	NO

Theory of permeation during hydration



MSDE

Molecular Systems Design & Engineering
rsc.li/molecular-engineering



ISSN 2058-9689

Question n. 2

Can a molecule be improved with regards to the liposome formulability?


Question(s) n. 2

Can a molecule be improved with regards to the liposome formulability?

Can a molecule be moved in LBCS space?


Question(s) n. 2 in LBCS space

Can we move a drug from one box to another?





Considered molecules for this problem

- 4 molecules from different LBCS classes
- Cytarabine „needs“ permeability increase
- Other 3 „need“ permeability decrease




Cytarabine permeability increase

- 3 ways to increase it: ester, amid, simple carbon chain addition





Cytarabine permeability increase results

- It works – permeability increases
- Partition coefficient changes not monotonously




Permeability decrease

- All 4 molecules taken as a starting points
- Fructose attachment was tested




Permeability decrease results

- Permeability does not always change
- Molecule modification is not universal




A-fru



molecular pharmaceutics

april 2023
volume 20 number 4
pubs.acs.org/molecularpharmaceutics



Question n. 3

Can the permeabilities be measured?


Question(s) n. 3

Can the permeabilities be measured?

Can the permeabilities of slow-permeating molecules be measured?


Permeability measurement common methods

- Caco-2, PAMPA





Permeability measurement

- The most common measurement methods – Caco-2, PAMPA





Utilisation of liposomes for permeation measurement

- Fluorescence-based method




Direct observation of permeation enhancement

- Two different known mechanisms directly observed



Co-permeation of other drugs

- Addition of second molecule affects both partitioning and permeability
- The consequences can be numerous



Marking of the sample	Permeability (cm/s)	Partition coefficient
CF	$(1.4 \pm 0.4) \cdot 10^{-8}$	1.6 ± 0.1
CF – CC,lip	$(2.2 \pm 0.7) \cdot 10^{-8}$	0.32 ± 0.09
CF – APIX,lip	$(3.1 \pm 0.4) \cdot 10^{-9}$	1.9 ± 0.1
CF – HCTZ,lip	$(1.1 \pm 0.1) \cdot 10^{-8}$	2.7 ± 0.3
CF – NX,lip	$(2.2 \pm 0.2) \cdot 10^{-8}$	2.1 ± 0.3

molecular pharmaceutics

june 2024
volume 21 number 6
pubs.acs.org/molecularpharmaceutics



Biomembrane permeability

- Critical parameter for drug formulability into liposomes
- Can be tuned using „right“ prodrugs
- Is **not** independent on other permeating molecules

Future work

- Deeper understanding of the cooperative permeation properties
- Application of the prodrugs
- Insight into the permeation measurement methods

Acknowledgement institutional



Pharmaceutical
Applied Research
Center

ZENTIVA




UNIVERSITY OF
CHEMISTRY AND TECHNOLOGY
PRAGUE



Faculty
of Science

Acknowledgement personal

- František Štěpánek, Karel Berka, Aleksandra Dumicic




Acknowledgement personal

- František Štěpánek, Karel Berka, Aleksandra Dumicic
- Klára Odehnalová, Martin Šrejber



Acknowledgement personal

- František Štěpánek, Karel Berka, Aleksandra Dumicic
- Klára Odehnalová, Martin Šrejber
- Kateřina Storchmannová, Marek Šoltys, Petra Janská, Aleš Zadražil



Acknowledgement personal

- František Štěpánek, Karel Berka, Aleksandra Dumicic
- Klára Odehnalová, Martin Šrejber
- Kateřina Storchmannová, Marek Šoltys, Petra Janská, Aleš Zdražil
- Cooperators on other publications, students



Discussed publications

Balouch, M.; Šrejber, M.; Šoltys, M.; Janská, P.; Štěpánek, F.; Berka, K., In silico screening of drug candidates for thermoresponsive liposome formulations. *Molecular Systems Design Engineering* **2021**, 6 (5), 368-380.

Balouch M.; Storchmannová K.; Štěpánek F.; Berka K., Computational prodrug design methodology for liposome formulability enhancement of small-molecule APIs, *Molecular Pharmaceutics* **2023**, 20 (4), 2119–2127

Odehnalová K. & Balouch M., Storchmannová K., Petrová E., Konefał M., Zadražil A., Berka K., Brus J., Štěpánek F., Liposomal co-permeation assay reveals unexpected membrane interactions of commonly prescribed drugs, *Molecular Pharmaceutics* **2024**, 21 (6), 2673–2683